Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to evaluate the long tern safety and effectiveness of cross-linking in eyes with keratoconus and ectasia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CXL Treatment | Experimental | All eyes to be treated with riboflavin and UV light |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Riboflavin | Drug | Riboflavin is a solution that will be delivered to the treatment area |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Corneal Curvature | 24 MO |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Barnet Dulaney Perkins Eye Center | Phoenix | Arizona | United States | |||
| Woolfson Eye Institute |
Enrolled participants were excluded from the clinical trial because they failed to meet one or more the inclusion/exclusion criteria.
The recruitment period started December 2010 and ended June 2012 at medical clinics throughout the country.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | CXL Treatment | All eyes to be treated with riboflavin and UV light |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| VEGA UV-A Illumination System |
| Device |
This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area |
|
| Atlanta |
| Georgia |
| United States |
| Massachusetts Eye And Ear Infirmary | Boston | Massachusetts | United States |
| Minnesota Eye Consultants | Bloomington | Minnesota | United States |
| Laser and Corneal Surgery Assoc. PC | New York | New York | 10022 | United States |
| Mt Sinai Hospital | New York | New York | United States |
| Pamel Vision & Laser Group | New York | New York | United States |
| Cleveland Clinic-Cole Eye Institute | Cleveland | Ohio | 44195 | United States |
| ReVision Advanced Laser Eye Center | Columbus | Ohio | 43240 | United States |
| OSU Department of Ophthalomogy | Columbus | Ohio | United States |
| Dell Laser Consultants | Austin | Texas | United States |
| Slade and Baker Vision Center | Houston | Texas | United States |
| The Eye Institute of Utah | Salt Lake City | Utah | 84107 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | CXL Treatment | All eyes to be treated with riboflavin and UV light |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Changes in Corneal Curvature | The CXL-003 study was terminated and data analysis was not done. The sponsor, Topcon Medical Systems, decided to terminate the study for administrative reasons only, and not as a result of any safety issues or concerns relating to the study. | Posted | 24 MO |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | CXL Treatment | All eyes to be treated with riboflavin and UV light | 0 | 372 | 0 | 372 |
Not provided
Not provided
All such Confidential Information shall remain the property of Topcon, as applicable, and Institution agrees that neither it nor Principal Investigator nor any of its employees or Sub-Investigators, if any, shall disclose any of the Confidential Information to third parties, without the prior written consent of Topcon.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Bob Gibson | Topcon Medical Systems | (201) 599-5121 | RGIBSON@TOPCON.COM |
| ID | Term |
|---|---|
| D007640 | Keratoconus |
| D004108 | Dilatation, Pathologic |
| ID | Term |
|---|---|
| D003316 | Corneal Diseases |
| D005128 | Eye Diseases |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D012256 | Riboflavin |
| ID | Term |
|---|---|
| D005415 | Flavins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D003067 | Coenzymes |
| D045762 | Enzymes and Coenzymes |
| D010860 | Pigments, Biological |
| D001685 | Biological Factors |
Not provided
Not provided